S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal Article
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
TL;DR: The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.
Journal ArticleDOI
Hypoxia-Induced Oxygen Tolerance: Maintenance of Endothelial Metabolic Function
TL;DR: In isolated perfused lungs 125I-MK351A binding reflects development of oxygen tolerance after hypoxia preadaptation and suggests that lung endothelial metabolic function is protected from oxygen toxicity.
Journal ArticleDOI
Altered responsiveness of regional brain dopamine and DOPAC levels to systemic administration of quinpirole, a dopamine D2 agonist, in DOCA/NaCl-hypertensive rats.
TL;DR: Quinpirole resulted in a significant increase in DA stores and decrease in DOPAC stores in most brain regions examined in both DOCA/NaCl-hypertensive rats and normotensive controls, presumably by inhibiting DA release through a presynaptic mechanism.
Journal ArticleDOI
Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.
Eduardo Pimenta,Suzanne Oparil +1 more
TL;DR: Large-scale, long-term studies are needed to confirm that olmesartan has vasoprotective effects that are independent of BP control and to determine whether these pleiotropic effects translate into improved CV disease outcomes.
Journal ArticleDOI
Efficacy of perindopril in the treatment of systemic hypertension
TL;DR: Perindopril increases arterial compliance and reverses left ventricular hypertrophy in hypertensive patients and is safe and well tolerated in patients with hypertension.